byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologici - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologici - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
yesafili
viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologici - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.
saflutan
santen italy srl - tafluprost - tafluprost
loyada
santen italy srl - timololo, associazioni - timololo, associazioni
saflutan monodose gocce oculari
santen sa - tafluprostum - monodose gocce oculari - tafluprostum 15 µg, glycerolum, natrii dihydrogenophosphas dihydricus corresp. phosphas 1.2 mg, dinatrii edetas, polysorbatum 80, acidum hydrochloridum aut natrii hydroxidum ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - glaucome - synthetika
taptiqom 15mcg/ml + 5mg/ml monodose gocce oculari
santen sa - tafluprostum, timololum - monodose gocce oculari - tafluprostum 0.015 mg, timololum 5.00 mg ut timololi maleas 6.84 mg, glycerolum, dinatrii phosphas dodecahydricus corresp. phosphas 1.34 mg, dinatrii edetas, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum, aqua ad iniectabile, ad solutionem pro 1 ml. - riduzione della pressione intraoculare elevata - synthetika
saflutan collyre (multidose)
santen sa - tafluprostum - collyre (multidose) - tafluprostum 15 µg, glycerolum, natrii dihydrogenophosphas dihydricus corresp. phosphas 1.2 mg, dinatrii edetas, polysorbatum 80, natrii hydroxidum aut acidum hydrochloridum ad ph, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - glaucome - synthetika
safluround
santen oy - tafluprost - tafluprost